Novartis has gone out of its way to persuade analysts that it is going all out to advance new medications in its pipeline. There are 139 new projects in clinical studies, including 88 new molecular entities--a 40 percent increase over 2005. And four out of every five compounds that demonstrated clinical proof-of-concept in 2006/2007 are now either in Phase II or Phase III.
Novartis pipeline highlights |
CLICK IMAGE FOR MORE |
"We are working to transition pharmaceuticals development into highly integrated teams that consistently deliver innovative medicines to patients with biotech-like intensity, focus and flexibility," said Trevor Mundel, MD, head of Global Development Function.
"Our strategy is working to deliver more effective medicines to patients rapidly," said Mark Fishman, MD, president of the Novartis Institutes for BioMedical Research. "In a relatively short time we have dramatically increased the size and power of our pipeline and believe many of these compounds have the potential to change the practice of medicine."
- read Novartis' release
- check out what's in the pipeline